• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice
Chronic kidney disease is common in patients with atrial fibrillation (AF) and is associated with heightened risks of stroke/systemic embolisation and bleeding. In this review we outline the evidence for AF stroke prevention in kidney disease, identify current knowledge gaps, and give recommendations for anticoagulation at various stages of chronic kidney disease.Overall, anticoagulation is underused. Warfarin use becomes increasingly difficult with advancing kidney disease, with difficulty maintaining international normalised ratio (INR) in therapeutic range, increased risk of intracranial and fatal bleeding compared to n...
Source: Heart, Lung and Circulation - November 3, 2022 Category: Cardiology Authors: Christopher Hammett, Sunil V. Badve, Peter G. Kerr, Huyen A. Tran, Benjamin K. Dundon, Sidney Lo, Andrew Wong, Joanne E. Joseph, Jenny Deague, Vlado Perkovic Tags: Review Source Type: research

516 Non-Vitamin K Anticoagulation for Non-Valvular Atrial Fibrillation in Regional Australia
Non-vitamin K antagonist oral anticoagulants (NOACs) are the therapy of choice for stroke prevention in patients with non-valvular atrial fibrillation and at least one risk factor. The Illawarra-Shoalhaven region local health district provides health services for around 400,000 people. In regional centres, many AF patients are managed by GPs. The purpose of this study was to identify the proportion of patients with NVAF who were prescribed different NOACs as well as determine if the dosage follows current guidelines.
Source: Heart, Lung and Circulation - November 8, 2020 Category: Cardiology Authors: J. Moragues Source Type: research